Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004959
Filing Date
2019-05-14
Accepted
2019-05-14 08:01:16
Documents
58
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20190331x10q.htm 10-Q 1224405
2 EX-31.1 ettx-20190331ex311db52b0.htm EX-31.1 15466
3 EX-31.2 ettx-20190331ex312090c9f.htm EX-31.2 14514
4 EX-32.1 ettx-20190331ex32112e850.htm EX-32.1 9981
  Complete submission text file 0001558370-19-004959.txt   4700299

Data Files

Seq Description Document Type Size
5 EX-101.INS ettx-20190331.xml EX-101.INS 904550
6 EX-101.SCH ettx-20190331.xsd EX-101.SCH 40172
7 EX-101.CAL ettx-20190331_cal.xml EX-101.CAL 47034
8 EX-101.DEF ettx-20190331_def.xml EX-101.DEF 157171
9 EX-101.LAB ettx-20190331_lab.xml EX-101.LAB 372595
10 EX-101.PRE ettx-20190331_pre.xml EX-101.PRE 269556
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 19820478
SIC: 2834 Pharmaceutical Preparations